Access to treatments and new drugs
We’re working to ensure that every person with migraine has access to the best and latest treatments
Access to new CGRP drugs for the prevention of migraine
Calcitonin Gene-Related Peptide (CGRP) drugs are the newest preventive medicines specifically developed and licensed for the treatment of migraine. CGRP is a neuropeptide that is released during migraine attacks and increases the activation of the nerves that relay headache and facial pain signals to the brain. CGRP drugs block the activity of this peptide and reduce the number of migraine attacks in patients. Some patients who have taken these drugs report significant improvements in their quality of life, describing them as ‘life changing.’
These new class of drugs are available privately in the UK. You can learn more about them here.
However, only one drug – Erenumab (Aimovig) – is available on the NHS and it is only available for chronic migraine patients who live in Scotland. The National Institute for Health and Care Excellence (NICE) recently rejected Aimovig for use on the NHS in England and Wales. You can read more about that decision and what it means for patients here.
Both NICE and the Scottish Medicines Consortium (SMC) are currently appraising another CGRP drug, Fremanezumab (Ajovy). The Migraine Trust is currently collecting new evidence to make the case to NICE and the SMC for these drugs to be available for all chronic migraine patients. We’ve been surveying people with migraine who have taken these drugs to learn from them about their experiences and better make the case for the benefits of this treatment.
You can see the latest results from our CGRP Patient Experience Survey below:
We will continue to make the case for migraine patients to have access to the best possible treatment that they and their clinician decide that they need.
You can learn more about what we’re doing and how you can get involved by subscribing to our monthly e-bulletin here.